Unavailable
Unavailable
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 5/11/2022 | Mkt Perform → Outperform | William Blair |
William Blair upgraded Novanta from Mkt Perform to Outperform
8-K - NOVANTA INC (0001076930) (Filer)
8-K - NOVANTA INC (0001076930) (Filer)
CERT - NOVANTA INC (0001076930) (Filer)
Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has priced its previously announced public offering of 11 million of its 6.50% tangible equity units at $50.00 per unit (equal to the stated amount per unit). The transaction is a public offering made by means of a prospectus supplement under Novanta's effective shelf registration statement. Novanta's common shares are quoted on Nasdaq under the ticker symbol "NOVT," and Novanta has applied to list the tangible equity units on Nasdaq under the symbol "NOVTU." Novanta anticipates that the offering will close on November 12,
Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has commenced a public offering of 11 million tangible equity units, with an aggregate stated amount of $550.0 million. Each tangible equity unit will have a stated amount of $50.00 and be comprised of a prepaid stock purchase contract and a senior amortizing note due 2028, each issued by Novanta. The tangible equity unit offering is a public offering made by means of a prospectus supplement under Novanta's effective shelf registration statement. Novanta's common shares are quoted on Nasdaq under the ticker symbol "NOVT," a
Third Quarter 2025 GAAP Revenue increased 1.4% to $247.8 million Third Quarter 2025 GAAP Net Income of $10.7 million Third Quarter 2025 GAAP Diluted Earnings Per Share of $0.30 Third Quarter 2025 Adjusted EBITDA of $58.1 million Third Quarter 2025 Adjusted EPS of $0.87 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) September 26, September 27, 2025 2024 GAAP
4 - NOVANTA INC (0001076930) (Issuer)
3 - NOVANTA INC (0001076930) (Issuer)
4 - NOVANTA INC (0001076930) (Issuer)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
SC 13G - NOVANTA INC (0001076930) (Subject)
SC 13G/A - NOVANTA INC (0001076930) (Subject)
IDEX Corporation (NYSE:IEX) today announced the appointment of Stephanie ("Steph") Disher and Matthijs Glastra to the company's Board of Directors. The appointments, effective Friday, February 21, 2025, increase the size of the Board from 10 to 12 directors. Ms. Disher will serve on the Board's Nominating and Corporate Governance Committee, and Mr. Glastra will serve on the Board's Audit Committee. Ms. Disher currently serves as Chief Executive Officer of Atmus Filtration Technologies Inc. (NYSE:ATMU), a leader in filtration and media solutions. She has extensive global leadership experience in finance and operations from her time at Atmus, Cummins Inc. and BP, p.l.c. Mr. Glastra currentl
Sends Letter to Masimo Shareholders and Releases 160-Page Investor Presentation Urges Shareholders to Help Deliver Immediate Change by Voting for Both of Politan's Independent and Ideally Qualified Nominees Darlene Solomon and William Jellison on the WHITE Card Shareholders Can Visit www.AdvanceMasimo.com for Further Information Politan Capital Management (together with its affiliates, "Politan"), an 8.9% shareholder of Masimo Corporation ("Masimo" or the "Company") (NASDAQ:MASI), today sent a letter to the Company's shareholders outlining why a majority of truly independent directors are urgently needed in the Masimo boardroom. Politan also released a detailed investor presentation m
Third Quarter 2025 GAAP Revenue increased 1.4% to $247.8 million Third Quarter 2025 GAAP Net Income of $10.7 million Third Quarter 2025 GAAP Diluted Earnings Per Share of $0.30 Third Quarter 2025 Adjusted EBITDA of $58.1 million Third Quarter 2025 Adjusted EPS of $0.87 Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) September 26, September 27, 2025 2024 GAAP
Novanta Inc. (NASDAQ:NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2025 results on Tuesday, November 4, 2025. The Company will host a conference call on Tuesday, November 4, 2025, at 8:30 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online via a live webcast on the Events & Presentations page of the Investors section of the Company's website at www.novanta.com. A replay of the audio webcast will be available approximately three hours after the conclusion of the ca
Second Quarter 2025 GAAP Revenue increased 2% to $241 million Second Quarter 2025 GAAP Net Income of $4.5 million Second Quarter 2025 GAAP Diluted Earnings Per Share of $0.12 Second Quarter 2025 Adjusted EBITDA of $52 million Second Quarter 2025 Adjusted EPS of $0.76 Company updates Full Year 2025 financial guidance Novanta Inc. (NASDAQ:NOVT) ("Novanta" or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2025. Financial Highlights Three Months Ended (In millions, except per share amounts) June 27, June 28,